What is AOD9604?
AOD9604 is a synthetic peptide carved from the tail end of human growth hormone: amino acids 176 to 191, the specific stretch decades of research identified as carrying the hormone's fat-burning activity, plus one stabilizing amino acid. The name you will also see is hGH fragment 176-191.
The design idea is surgical: full growth hormone burns fat, but it also raises blood sugar and drives general tissue growth. Isolate just the fat-handling segment, and in principle you keep the metabolic upside without the hormonal load. Unusually for this library, that idea was actually taken through a full human obesity trial program, which makes AOD9604's story more instructive than most.
How does it work?
The mechanism centers on lipolysis, fat cells releasing stored fat to burn. A 2000 study found AOD9604 increased lipolytic activity in the fat tissue of obese rats and cut weight gain by more than half. A 2001 study in Endocrinology mapped the pathway: both full growth hormone and the fragment restored activity of the beta-3 adrenergic receptor, a fat-burning switch suppressed in obesity, and in mice engineered without that receptor the sustained fat loss disappeared, while an acute boost in fat oxidation survived, so the fragment works through more than one route.
Crucially, it does all this without raising blood sugar the way whole growth hormone does, which was the entire point of the design.
Why it matters
AOD9604 matters partly for what it is and partly for what it teaches. What it is: a growth-hormone-derived fat compound without the glucose penalty, still popular in body-composition protocols. What it teaches: it is one of the few compounds in this library that got its big human trials, and the results came back more modest than the animal work promised, a pattern worth internalizing for every mouse-stage compound sold with confidence.
What the human trials found
Metabolic Pharmaceuticals ran a genuine human obesity program. The consistent good news: AOD9604 was safe and well tolerated across the trials, oral dosing included, with no growth-hormone-style effects on blood sugar. The efficacy news: early dosing produced more weight loss than placebo, and the largest trials did not reach their primary weight-loss endpoint, which is why the program stopped and why there is no approved product today.
The research thread did not die; it turned. A 2015 study and subsequent work explored the fragment in cartilage repair, injected intra-articularly alongside hyaluronic acid in osteoarthritis models, with improved cartilage outcomes in animals, a second life that keeps AOD9604 in regenerative conversations beyond fat loss.
What people notice in practice
What users report, labeled honestly as experience rather than trial evidence, is modest recomposition: stubborn-fat areas softening over weeks, slightly easier cutting phases, usually via subcutaneous injection despite the trials having tested oral dosing. Plenty report nothing, which happens to match the trial arc better than the marketing does.
The honest framing writes itself here: this is a compound whose human trials exist and read "safe, tolerable, weaker than hoped." Practice enthusiasm that exceeds that verdict is running on the animal data the trials already audited.
The pros and the cons
What's promising
- A rational design that demonstrably avoids growth hormone's blood-sugar effects.
- Real human trials showing safety and good tolerability, including oral dosing.
- Consistent animal evidence for increased fat release and oxidation.
- A genuine second research life in cartilage repair.
What's uncertain
- The largest human trials missed their primary weight-loss endpoint.
- No approval anywhere; the obesity program ended without a product.
- The cartilage work is animal-stage.
- Practice injection routes differ from the oral dosing the trials tested.
Worth considering
- Modern metabolic medications with proven endpoints exist; AOD9604 competes against them now.
- The safety record is genuinely reassuring, which is not the same as the efficacy case.
- Sourcing quality is the standing gray-market question.
- For joint uses, the evidence is animal-model, and expectations belong there.
What its trial history teaches
AOD9604 is the rare compound in this library that got its audit. The animal data looked the way BPC-157's and 5-Amino-1MQ's look today: consistent, mechanistic, exciting. The human program then delivered safety, tolerability, and an efficacy result too small to win. That arc, promising preclinical, modest clinical, is the single most common outcome in drug development, and it is the calibration we recommend applying to every never-tested compound on this site.
What the key studies tested
Our framing rule for evidence: a study tests one dose, one route, one population, one endpoint. Where the evidence sits:
Preclinical & practice
The lipolysis mechanism work, the cartilage models, and current practice use.
Early trials
Early human dosing with weight loss beating placebo.
Late-stage trials
The full obesity program: safe and well tolerated; primary endpoints not met in the largest trials.
Approved uses
None, anywhere.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
Is AOD9604 just growth hormone lite?
It is growth hormone's fat-burning tail with the rest deliberately left behind: no blood-sugar rise, no general growth signaling, no IGF-1 axis push. That selectivity was demonstrated, and it is the honest good news of the whole program. The efficacy that survived the subtraction proved smaller than hoped, which is the other half.
Did the human trials fail?
They half-succeeded, precisely: safety and tolerability were clean throughout, early dosing beat placebo on weight, and the largest trials missed their primary weight-loss endpoints, ending the program. In drug development that counts as failure; as information, it is a rare, valuable audit of a peptide class that mostly never gets one.
What is the cartilage story?
A second research thread: animal studies found intra-articular AOD9604 alongside hyaluronic acid improved cartilage repair outcomes in osteoarthritis models. It keeps the fragment interesting in regenerative joint conversations, at the animal-evidence tier, with no human joint trials run.
Is AOD9604 safe?
Its human program is actually the reassurance: repeatedly safe and well tolerated in trials, without glucose effects. The standing caveats are the practical ones, gray-market sourcing, and practice injection routes that differ from the oral dosing most of the trials studied.
What to take away
If you remember five things from this article, make them these:
- AOD9604 is growth hormone's fat-burning fragment, engineered to drop the blood-sugar and growth effects.
- The animal evidence was strong and the design goal, selectivity, genuinely worked.
- Its human obesity trials delivered safety and tolerability, and missed the big efficacy endpoints.
- A second life in cartilage repair is real and animal-stage.
- Its trial arc is the calibration lesson for every promising mouse-stage compound in this library.
The evidence
Selected references, each verified against primary sources (PubMed, ClinicalTrials registries, and peer-reviewed journals). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. AOD9604 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.